AUTHORS
Maria Virginia Ruiz Cuevas, PhD, Susan Klaeger, PhD2, Marwan Kwok, MD, PhD, MRCP, FRCPath3, Eugen Tausch, MD, PhD4, Emma S Lin5, Binyamin Knisbacher, PhD6, Clary Clish7, Anne-Marie Hewitt8, Monica Spydell9, Emanuela M. Ghia, PhD10, Laura Z Rassenti, PhD11, Michael Gillette12, Gaddy Getz, PhD13, Donna Neuberg, ScD14, Thomas J Kipps, MD, PhD15, D. R. Mani16, Karl R. Clauser17, Jenn G Abelin, PhD18, Stephan Stilgenbauer, MD19, Steven Carr20, Catherine J. Wu, MD21
AFFILIATIONS
1 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States
2 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, University of Birmingham, Birmingham, United Kingdom
4 Ulm University, Ulm, Germany
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Bar-Ilan University, Ramat Gan, Israel, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States
8 Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, University of Birmingham, Birmingham, United Kingdom
9 University of California San Diego, La Jolla, California, United States
10 University of California San Diego, La Jolla, California, United States
11 University of California San Diego, La Jolla, California, United States
12 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
13 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 University of California San Diego, La Jolla, California, United States
16 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States
17 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States
18 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
19 Ulm University, Ulm, Germany
20 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States
21 Brigham and Women’s Hospital, Boston, Massachusetts, United States, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
ABSTRACT
Mutations in the U2 snRNP spliceosome component SF3B1 are common in chronic lymphocytic leukemia (CLL), associate with inferior clinical outcomes, and drive widespread use of aberrant 3′ splice sites that remodel the transcriptome. However, how these splicing alterations reshape the proteome and signaling networks of CLL cells to create targetable tumor-intrinsic vulnerabilities remains unknown.
We performed integrated whole-exome sequencing, RNA-seq, TMT-based proteomics, phosphoproteomics, and metabolomics across 105 primary CLL samples stratified by SF3B1 mutation status (53 SF3B1mut, 52 SF3B1WT). Using unsupervised non-negative matrix factorization (NMF) clustering, we identified three subtypes (C1, C2, C3) associated with SF3B1 status. A distinct cluster containing only mut-SF3B1 samples was identified and revealed extensive cellular reprogramming in SF3B1mut versus SF3B1WT CLL that was more prominent at the protein than transcript level, recapitulating enhanced MYC pathway activation and uncovering additional differentially enriched biological processes in cellular energetics and nucleotide metabolism. SF3B1mut CLL also showed consistent downregulation of key immune and signaling pathways, including TNF-α/NF-κB signaling and both type I (IFN-I, e.g. IFN-α) and type II interferon (IFN-II, e.g. IFN-γ) responses, supporting the association with an immunoevasive phenotype.
Regarding bioenergetics, SF3B1mut CLL showed marked enrichment of oxidative phosphorylation (OXPHOS) and fatty acid metabolism, evidenced by upregulation of mitochondrial complex II subunits SDHA and SDHB alongside depletion of succinate and polyunsaturated fatty acids, consistent with heightened consumption by hyperactivated OXPHOS and fatty acid metabolism. Corroborating functional OXPHOS dependence, SF3B1mut primary CLL cells exhibited greater sensitivity to selective mitochondrial OXPHOS inhibition than SF3B1WT CLL, with IACS-010759 (250 nM, 4 days) inducing 49% versus 23% cell death (n=8 per group, p=0.049), with similar trends observed for atovaquone.
In reference to nucleotide metabolism, SF3B1mut CLL displayed substantial depletion of the purine metabolites inosine monophosphate (SF3B1mut/SF3B1WT ratio 0.37) and hypoxanthine (ratio 0.56), likely precipitating replication fork stalling and replication stress. Concurrently, we observed marked enrichment of phosphatidylinositols (PIs) (e.g., PI 36:2; SF3B1mut/SF3B1WT ratio 1.72, p=0.009), a localized lipid accumulation known to facilitate ATR-mediated DNA damage signaling and checkpoint activation, accompanied by downregulation of mitotic spindle proteins in our proteomic data. Consistent with enhanced ATR dependence, SF3B1mut primary CLL samples showed significantly increased sensitivity to the ATR inhibitor ceralasertib compared with SF3B1WT samples (EC50 values shifted towards lower concentrations in SF3B1mut CLL, p=0.01).
To better understand the observed downregulated immune pathways in SF3B1mut CLL, we investigated antigen presentation by performing HLA-I immunopeptidomics in 25 CLL samples (9 SF3B1WT, 16 SF3B1mut) and identified a panel of leukemia-restricted antigens spanning non-canonical open reading frames, leukemia-associated antigens, cancer-testis antigens, and peptides derived from somatically mutated VDJ sequences. Notably, we observed T-cell responses to AQSAFTAY, a noncanonical peptide selectively presented by SF3B1mut CLL and predicted to bind the common HLA-A*01:01 allele, supporting the existence of SF3B1-mutation–linked immunogenic targets.
Collectively, our data identify proteome-centered reprogramming as a defining feature of SF3B1mut CLL. We uncovered tractable vulnerabilities, including dependence on mitochondrial OXPHOS and ATR signaling, as well as presentation of leukemia-restricted antigens. Our findings support rational combination strategies incorporating OXPHOS and ATR inhibitors, and antigen-directed immunotherapies, in this high-risk molecular subset.
DISCLOSURES
Marwan Kwok, MD, PhD, MRCP, FRCPath: No relevant conflicts of interest to declare.